Why Moderna Stock Is a No-Brainer Buy Right Now

This messenger-RNA pioneer should be able to keep its rebound going. Some investors might view Moderna (MRNA -2.38%) as a shooting star that shined bright for a while then flamed out. In 2022, the biotech company generated sales of nearly $18.9 billion, but it expects revenue of only $4 billion this year. The real story for Moderna is much better than that steep sales decline reflects. Here's why the biotech stock is a no-brainer buy right now. At an inflection point It's no exaggeration to say that Moderna ...